Tags : Hydroxychloroquine
In late 2019, a mysterious virus causing infection consisting of dry cough, fever tiredness, and last pneumonia first appeared in Wuhan, China. The world health organization (WHO) named the disease as Coronavirus 2019 (Covid-19). Interestingly, Covid-19 and flu (caused by influenza virus) share the common disease progression asymptomatic (no symptoms), mild symptoms fever or chills, […]Read More
Shots: Novartis has discontinued its clinical trial HCQs due to feasibility of recruitment. The recruitment challenge has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19 Novartis will continue to supply HCQ for ongoing IITs […]Read More
Shots: Novartis to initiate the P-III clinical study to assess hydroxychloroquine vs hydroxychloroquine + azithromycin vs PBO in 440 patients with COVID-19 at more than a dozen sites in the US. The drug will be supplied by Sandoz while Novartis intends to initiate the enrollment for the study within the next few weeks Novartis will […]Read More
